Best AgrolifeQ2 FY24

Best Agrolife Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹14.65P/E: 10.8Market Cap: ₹520 CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • The company targets a revenue growth of 25% to 30% year-on-year for FY24 and beyond.
  • Formulation segment (branded products) contribution has increased to over 70%, indicating strong growth drivers.
  • Volume growth for key products last year was around 30%, with expected continued growth.
  • Upcoming patented molecules and new products like Orisulam (seed treatment) are expected to fuel future growth.
  • The company is investing heavily in field assistance (~1,000+ field staff) and marketing to drive farmer adoption.
  • Export revenue is expected to start low (~$1 million/year initially), growing to $10-30 million per year within 5 years through international registrations and market expansion.
  • CAPEX focused on backward integration and formulation capacity will support sustainable growth and improve EBITDA margins by 3-5%.
  • Overall, a strong product pipeline and market expansion plan underpin growth confidence.

See what Best Agrolife management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The transcript does not mention any current or planned fundraising through debt or equity.
  • There is no specific discussion about raising capital via new debt or equity issuance.
  • The company is focusing on a Rs. 200 crore CAPEX largely funded internally, mainly for backward integration and capacity expansion.
  • The management emphasizes improving working capital and cash conversion cycle to support operations.
  • No explicit reference to equity or debt financing plans was provided in the Q2 FY24 earnings call transcript.

See what Best Agrolife management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Best Agrolife has announced a total CAPEX of approximately Rs. 200 crores for the full year.
  • Around Rs. 130 crores of this CAPEX is expected to be spent by year-end FY24.
  • Majority (about Rs. 150 crores) of the CAPEX will be allocated to backward integration projects focusing on "Make in India" for strobin chemistry products.
  • Remaining CAPEX will be used for capacity addition in formulation, including the recent acquisition of Kashmir Chemical (formulation manufacturing).
  • The CAPEX aims to expand manufacturing capacity to meet growing demand for branded agrochemical formulation products.
  • This investment supports new product launches, backward integration, and increased production efficiency.
  • Long-term focus on backward integration is expected to improve EBITDA margins by 3% to 5%.
  • Ongoing strategic moves include international expansion and migration to SAP HANA S4 ERP for better operational efficiency.

Track Best Agrolife — get its next earnings analysis in your feed

How does Best Agrolife rank vs peers in Fertilizers & Agrochemicals?

Pro feature
ThisBest Agrolife
Rev 2Mar 1

How does Best Agrolife rank in Fertilizers & Agrochemicals?

Compare Best Agrolife against every Fertilizers & Agrochemicals company (Q2 FY24) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

Others in Fertilizers & Agrochemicals this season

  • Madhya Bharat Agro Products (Q2 FY27)

    Q2 FY27 Revenue: ₹715 crore, up 59% YoY (Page 12, Chairman’s Quote) . Key investor presentation takeaways from Madhya Bharat Agro Products Ltd's Q2 FY27 investo

  • Dhansa Labs (Q2 FY27)

    1,864 crores during H1 FY27. Key results statement takeaways from Dhansa Labs Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Aristo Bio-Tech (Q2 FY27)

    1,168.88 lakh, approximate operating margin is about 5.9% for the quarter. Key results statement takeaways from Aristo Bio-Tech & Lifescience Ltd's Q2 FY27 resu

  • Krishana Phoschem (Q2 FY27)

    Q2 FY27 Revenue: ₹703 crore, a 16% year-on-year (YoY) increase (Page 11). Key investor presentation takeaways from Krishana Phoschem Ltd's Q2 FY27 investor pres

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →